Immunoglobulin Market to rise to USD 22.32 billion by the end of 2030
The Global Immunoglobulin Market size is estimated to be USD 11.28 billion in 2019 and is predicted to reach USD 22.32 billion by 2030 with a CAGR of 6.4% from 2020-2030. Immunoglobulin’s are glycoprotein produced by plasma cells and act as antibody which activates the immune system for the production of antibodies against disease causing agents such as virus, bacteria and others. These are highly complex in nature and structure and exceedingly specific. There are classified into different classes and isotopes, biological features, target structure and others.
Read Report Overview @
https://www.nextmsc.com/report/immunoglobulin-market
The developing healthcare facilities and infrastructure coupled with increase in geriatric population and increased prevalence of hemophilia are expected to drive the market growth. Furthermore, technological advancement, and various purification techniques are also expected to promote the growth of immunoglobulin market.
There are various other factors contributing the market growth include increased prevalence of various chronic inflammatory disease coupled with increased awareness with reduced side effects are expected to promote the market growth. However, stringent government regulations coupled with increased risk of side effects are expected to hamper the growth of immunoglobulin market. Research and development activities coupled with wide applications are expected to create lucrative opportunities in the immunoglobulin market in the near future.
Market Segmentations and Scope of the Study:
The global immunoglobulin market share is analyzed on the basis of product, application, mode of application and geography. On the basis of product, the market is segmented into IgG, IgA, IgM, IgE, and IgD. On the basis of application, the market is divided into Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura (ITP), Inflammatory Myopathies, Specific Antibody Deficiency, Guillain?Barré Syndrome, and Others. On the basis of mode of delivery, the market is divided into Intravenous and Subcutaneous. The intravenous segment is further divided into 5% Concentration, 10% Concentration, and Others. The Subcutaneous segment in further segmented into 16.5% Concentration, 20% Concentration, and Others Geographic breakdown and analysis of each of the aforesaid segments includes regions comprising North America, Europe, Asia-Pacific, and RoW.
Geographical Analysis
North America represents the developed market are expected to hold the major market share owing to the presence of develop economies coupled with increased prevalence of hemophilia, developed healthcare facilities and infrastructure and technological enhancement for the purification are expected to fuel the growth of immunoglobulin market over the forecast period.
Asia Pacific is expected to develop tremendously with gradual increase in market share owing of the increasing accessibility to healthcare facilities, increase in various inflammatory disease, increase in geriatric population is expected to further promote the growth of immunoglobulin market.
Competitive Landscape
The immunoglobulin market, which is highly competitive, consists of a various market players. There are various players present in the market which contribute the overall market size. Some of the key players are CSL Ltd., Baxter international Inc., Octapharma AG, Grifols S.A, LFB group, Kedrion Biopharma Inc., China Biologics Products, Inc., Biotest AG, Shire (Baxalta), and Bayer Healthcare among others.
Request to view Sample Report:
https://www.nextmsc.com/immunoglobulin-market/request-sample
There have been various developments taken place in the recent past which is contributing to the growth immunoglobulin market. For instance, in January 2019, Kedrion Biopharma announced that the U.S. Food and Drug Administration has accepted their Investigational New Drug (IND) application for a clinical study aimed at assessing efficacy and safety of a 10% intravenous immunoglobulin in the treatment of adult patients with primary immunodeficiency diseases (PID). This approval allows Kedrion to initiate clinical trial in the United States in coming months.